JAGX - Jaguar Health, Inc.
| Previous Close | 0.578 |
| Open | 0.570 |
| Bid | 0.000 x 1200 |
| Ask | 0.000 x 800 |
| Day's Range | 0.540 - 0.652 |
| 52 Week Range | 0.500 - 7.500 |
| Volume | 385,010 |
| Avg. Volume | 173,285 |
| Market Cap | 7.964M |
| Beta | -1.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.016 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.25 |
- GlobeNewswire•28 days ago
Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health — What Drives Growth in Today's Competitive Landscape
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...
- GlobeNewswire•2 months ago
RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi®
Mytesi ® is an FDA-approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy Mytesi ® is the fourth product ...
- ACCESSWIRE•2 months ago
New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time
SAN FRANCISCO, CA / ACCESSWIRE / July 24, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), announced today the results of an analysis conducted to examine whether the rate of HIV-associated diarrhea has changed over time. The analysis of data, sourced from the National Institutes of Health (NIH) clinicaltrials.gov database, revealed that 18% of HIV patients experience diarrhea and the rates have not declined significantly over time. The analysis includes data from 38 U.S. clinical trials from 2008-2016 in more than 21,000 patients.
- ACCESSWIRE•2 months ago
Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).
- ACCESSWIRE•2 months ago
Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference
Presentation Will Cover New Data on the Incidence and Prevalence of Diarrhea in HIV Clinical Trials in the Recent Post-Combined Antiretroviral Therapy (cART) Era SAN FRANCISCO, CA / ACCESSWIRE / July 16, ...
- ACCESSWIRE•2 months ago
Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced financial updates today for the second quarter ended June 30, 2018. Achieved 125% growth in gross sales of Mytesi for the first six-months of 2018 versus the same period in 2017, and 120% growth in gross sales of Mytesi in the second quarter of 2018 compared to the second quarter of 2017. Continued expansion of the U.S. Napo direct sales organization through the hire of sales representatives with extensive HIV-related experience.
- ACCESSWIRE•3 months ago
Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product
SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), today announced that it has entered into an agreement (the Agreement) with RedHill Biopharma Ltd. (RedHill) (RDHL), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, to establish a U.S. co-promotion program for Mytesi® (crofelemer 125 mg delayed-release tablets), Napo's FDA-approved drug, for the current approved indication. Mytesi is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).
- GlobeNewswire•3 months ago
RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
RedHill has been granted the exclusive right to co-promote Mytesi ® in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by ...
- ACCESSWIRE•3 months ago
Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors
SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has appointed David MacNaughtan, an executive with more than 25 years of biopharmaceutical industry experience with roles spanning financing, venture capital, royalty investing, business development, and process development, to the Company's board of directors. Most recently, Mr. MacNaughtan led the intellectual property investing strategy at CPPIB Credit Investments Inc., a wholly-owned subsidiary of the Canada Pension Plan Investment Board, for eight years, focused on the acquisition and securitization of pharmaceutical royalty streams.
- ACCESSWIRE•3 months ago
Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors
SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has appointed Greg Divis, an executive with more than 28 years of direct operating and global leadership experience in specialty pharmaceuticals, to the Company's board of directors. Mr. Divis currently serves as the Chief Operating Officer of Avadel Pharmaceuticals, an emerging branded specialty pharmaceutical company he joined in 2017.
- ACCESSWIRE•3 months ago
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
- ACCESSWIRE•3 months ago
Napo Pharmaceuticals Presents New Data at the 13th International Conference on HIV Treatment and Prevention Adherence Regarding the Use of Mytesi (Crofelemer) to Treat Noninfectious Diarrhea in HIV Patients
SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), announced today the presentation of the data from the long-term Phase 3 trial (ADVENT) of Mytesi® (crofelemer) in patients with HIV-related diarrhea. The ADVENT study was a multicenter, randomized, placebo-controlled trial that enrolled 274 patients treated with either Mytesi 125mg bid or placebo.
- ACCESSWIRE•4 months ago
Today's Research Reports on Stocks to Watch: Co-Diagnostics and Jaguar Health
NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Shares of Co-Diagnostics Inc. was exploding on Friday after the company announced its CoPrimer™ technology is being employed to achieve the objectives of a research ...
- Simply Wall St.•4 months ago
Is Jaguar Health Inc’s (NASDAQ:JAGX) Balance Sheet Strong Enough To Weather A Storm?
Jaguar Health Inc (NASDAQ:JAGX) is a small-cap stock with a market capitalization of US$23.42M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
- ACCESSWIRE•4 months ago
Jaguar Health, Inc. Announces 1-for-15 Reverse Stock Split
SAN FRANCISCO, CA / ACCESSWIRE / June 1, 2018 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has effected a reverse stock split of its issued and outstanding voting common stock (''Common Stock''), at an exchange ratio of 1-for-15 (the ''Reverse Stock Split''), on Friday, June 1, 2018 (the ''Effective Date''). The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol ''JAGX''.
- ACCESSWIRE•4 months ago
Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals
SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has appointed Robert J. Griffing, an accomplished pharmaceutical and biotech executive, as chief commercialization officer of Napo Pharmaceuticals, Inc. (Napo), the Company's wholly-owned subsidiary focused on human health. In his role as CCO, Mr. Griffing will lead commercialization efforts for Mytesi®, Jaguar's FDA-approved, first-in-class drug product.
- ACCESSWIRE•4 months ago
Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders
SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2018 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company filed on May 15, 2018 its first quarter report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC). The Company also today announced voting results from Jaguar's 2018 Annual Meeting of Stockholders, which was held earlier today. Additionally, Jaguar announced today that Company management is hosting a conference call on Monday, May 21st at 4:30 p.m. Eastern Time for investors and analysts.
- Simply Wall St.•4 months ago
Jaguar Health Inc (NASDAQ:JAGX): Does The Earnings Decline Make It An Underperformer?
After looking at Jaguar Health Inc’s (NASDAQ:JAGX) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...
- ACCESSWIRE•4 months ago
''Under Pressure'' Episode of Merce Uses Comedy to Help People Living with HIV Talk About Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), announced today that, in conjunction with its continuing efforts to raise awareness around the problem of HIV-related diarrhea, the Company is supporting the production of Merce, an award-winning musical comedy web series about a middle-aged, HIV-positive man living in New York City, which aims to show that 'Life can be positive when you're positive!' A special short episode called ''Under Pressure'' has been produced by the Merce team that Napo will use in its awareness campaign. The episode can be viewed at http://enoughdiarrhea.com/video.html.
- ACCESSWIRE•4 months ago
Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks
Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.
- ACCESSWIRE•5 months ago
Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea
Mytesi for HIV-related Diarrhea Now on ADAP Formularies in 22 States SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), ...
- ACCESSWIRE•5 months ago
Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi
Agreement Provides Pricing for Mytesi to Each U.S. State's AIDS Drug Assistance Program (ADAP) - Organizations that Provide HIV-related Services and Approved Medications to More than Half a Million People ...
- ACCESSWIRE•6 months ago
Jaguar Health Appoints Jonathan B. Siegel to Board of Directors
SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on ...
